Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
- PMID: 24104550
- DOI: 10.1093/carcin/bgt333
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
Abstract
MicroRNAs (miRNAs) are endogenous non-coding RNAs, which play an essential role in the regulation of gene expression during carcinogenesis. The role of miRNAs in breast cancer has been thoroughly investigated, and although many miRNAs are identified as cancer related, little is known about their involvement in benign tumors. In this study, we investigated miRNA expression profiles in the two most common types of human benign tumors (fibroadenoma/fibroadenomatosis) and in malignant breast tumors and explored their role as oncomirs and tumor suppressor miRNAs. Here, we identified 33 miRNAs with similar deregulated expression in both benign and malignant tumors compared with the expression levels of those in normal tissue, including breast cancer-related miRNAs such as let-7, miR-21 and miR-155. Additionally, messenger RNA (mRNA) expression profiles were obtained for some of the same samples. Using integrated mRNA/miRNA expression analysis, we observed that overexpression of certain miRNAs co-occurred with a significant downregulation of their candidate target mRNAs in both benign and malignant tumors. In support of these findings, in vitro functional screening of the downregulated miRNAs in non-malignant and breast cancer cell lines identified several possible tumor suppressor miRNAs, including miR-193b, miR-193a-3p, miR-126, miR-134, miR-132, miR-486-5p, miR-886-3p, miR-195 and miR-497, showing reduced growth when re-expressed in cancer cells. The finding of deregulated expression of oncomirs and tumor suppressor miRNAs in benign breast tumors is intriguing, indicating that they may play a role in proliferation. A role of cancer-related miRNAs in the early phases of carcinogenesis and malignant transformation can, therefore, not be ruled out.
Similar articles
-
DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.Gene. 2017 Mar 10;604:1-8. doi: 10.1016/j.gene.2016.12.018. Epub 2016 Dec 18. Gene. 2017. PMID: 27998789
-
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis.Genes Chromosomes Cancer. 2009 Jul;48(7):615-23. doi: 10.1002/gcc.20669. Genes Chromosomes Cancer. 2009. PMID: 19396864
-
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.Hepatology. 2008 Jun;47(6):1955-63. doi: 10.1002/hep.22256. Hepatology. 2008. PMID: 18433021
-
Regulation of the MIR155 host gene in physiological and pathological processes.Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Gene. 2013. PMID: 23246696 Review.
-
MicroRNA involvement in the pathogenesis and management of breast cancer.J Clin Pathol. 2009 May;62(5):422-8. doi: 10.1136/jcp.2008.060681. J Clin Pathol. 2009. PMID: 19398594 Review.
Cited by
-
MiR-486-5p Act as a Biomarker in Endometrial Carcinoma: Promotes Cell Proliferation, Migration, Invasion by Targeting MARK1.Onco Targets Ther. 2020 May 28;13:4843-4853. doi: 10.2147/OTT.S246841. eCollection 2020. Onco Targets Ther. 2020. PMID: 32547110 Free PMC article.
-
MicroRNA-193b regulates human ovarian cancer cell growth via targeting STMN1.Exp Ther Med. 2020 Oct;20(4):3310-3315. doi: 10.3892/etm.2020.9033. Epub 2020 Jul 23. Exp Ther Med. 2020. PMID: 32855702 Free PMC article.
-
Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p.Int J Med Sci. 2022 Jan 16;19(2):338-351. doi: 10.7150/ijms.66040. eCollection 2022. Int J Med Sci. 2022. PMID: 35165519 Free PMC article.
-
MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin.Int J Mol Sci. 2014 Dec 2;15(12):22128-41. doi: 10.3390/ijms151222128. Int J Mol Sci. 2014. PMID: 25474084 Free PMC article.
-
miR-486-5p Serves as a Diagnostic Biomarker for Sepsis and Its Predictive Value for Clinical Outcomes.J Inflamm Res. 2021 Jul 30;14:3687-3695. doi: 10.2147/JIR.S323433. eCollection 2021. J Inflamm Res. 2021. PMID: 34354365 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical